XPORT-MF-034: A Phase 1 / Phase 3 Study to Evaluate the Efficacy and Safety of Selinexor, A Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment-Naïve Patients with Myelofibrosis
- Title
- A Phase 1 / Phase 3 Study to Evaluate the Efficacy and Safety of Selinexor, A Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment-Naïve Patients with Myelofibrosis
- Principal Investigator
- Bhatnagar, Bhavana
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Other Cancers
- Participating Institutions
- Wheeling Hospital
- Contacts
- Maher Kali, MD
- Clinical Research Specialist-WVUCI
- Phone: +1 304-243-7045
- Email: maher.kali@wvumedicine.org